- Home
- IOR vs ADAP Comparison
IOR vs ADAP Comparison
Compare IOR & ADAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOR
- ADAP
- Stock Information
- Founded
- IOR 1984
- ADAP 2008
- Country
- IOR United States
- ADAP United Kingdom
- Employees
- IOR N/A
- ADAP N/A
- Industry
- IOR Real Estate Investment Trusts
- ADAP Biotechnology: Pharmaceutical Preparations
- Sector
- IOR Real Estate
- ADAP Health Care
- Exchange
- IOR Nasdaq
- ADAP Nasdaq
- Market Cap
- IOR 72.8M
- ADAP 75.5M
- IPO Year
- IOR N/A
- ADAP 2015
- Fundamental
- Price
- IOR $18.64
- ADAP $0.35
- Analyst Decision
- IOR
- ADAP Buy
- Analyst Count
- IOR 0
- ADAP 6
- Target Price
- IOR N/A
- ADAP $1.35
- AVG Volume (30 Days)
- IOR 497.0
- ADAP 745.6K
- Earning Date
- IOR 08-07-2025
- ADAP 08-11-2025
- Dividend Yield
- IOR N/A
- ADAP N/A
- EPS Growth
- IOR N/A
- ADAP N/A
- EPS
- IOR 1.10
- ADAP N/A
- Revenue
- IOR N/A
- ADAP $179,639,000.00
- Revenue This Year
- IOR N/A
- ADAP N/A
- Revenue Next Year
- IOR N/A
- ADAP $37.22
- P/E Ratio
- IOR $17.00
- ADAP N/A
- Revenue Growth
- IOR N/A
- ADAP 878.53
- 52 Week Low
- IOR $15.69
- ADAP $0.20
- 52 Week High
- IOR $19.69
- ADAP $1.48
- Technical
- Relative Strength Index (RSI)
- IOR 51.09
- ADAP 75.18
- Support Level
- IOR $18.02
- ADAP $0.27
- Resistance Level
- IOR $18.89
- ADAP $0.36
- Average True Range (ATR)
- IOR 0.18
- ADAP 0.02
- MACD
- IOR -0.02
- ADAP 0.01
- Stochastic Oscillator
- IOR 41.34
- ADAP 90.51
About IOR Income Opportunity Realty Investors Inc.
Income Opportunity Realty Investors Inc is a U.S.-based company that is an externally managed company that invests in mortgage notes receivables and real property. The business of the company is managed by Pillar Income Asset Management, Inc. The company's activities include locating, evaluating and recommending investment opportunities. Pillar also arranges its debt and equity financing with unaffiliated independent third party lenders and investors.
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.